Study population
The non-randomized study population consisted of 80 consecutive patients undergoing CB ablation at two centers. The first 40 patients undergoing PVI using a standardized ablation protocol with the NCB (28-mm, short-tip POLARx, Boston Scientific) and 40 preceding patients using the SCB (28-mm Arctic Front Advance Pro, Medtronic, Minneapolis, MN, USA) were included at two centers. Exclusion criteria were the presence of long-standing persistent AF and a history of a previous left atrial procedure for PVI. Intracardiac thrombi were ruled out by transesophageal echocardiography before the procedure. All patients underwent pre-procedural imaging, either by computed tomography or by cardiac magnetic resonance imaging. Written informed consent was provided by all patients prior to the procedure. The study was approved by the local ethics committee on human research and complied with the Declaration of Helsinki.
Cryoballoon ablation using the standard cryoballoon
The ablation procedure was performed under conscious sedation using midazolam, fentanyl, and propofol. Vascular access was obtained via the right femoral vein. A decapolar deflectable catheter (EZ STEER, Biosense Webster, Diamond Bar, CA, USA; or Dynamic XT, Boston Scientific) was positioned in the right subclavian vein for pacing of the phrenic nerve during ablation of all right superior PVs. Phrenic nerve capture was confirmed by continuous palpation and/or monitoring of the compound motor action potential on the surface ECG. Transseptal puncture was performed under fluoroscopic guidance. The activated clotting time was kept at a target of 350 s using intravenous heparin. The intracardiac electrograms and surface electrograms were displayed on an oscilloscope and recorded at a speed of 100 mm/s (Sensis, Siemens, Erlangen, Germany).
In the SCB group, the steerable 12F inner (15F outer) diameter sheath (FlexCath Advance, Medtronic, MN, USA) was positioned in the left atrium after transseptal puncture and was continuously flushed with heparinized saline. The sheath has a radiopaque marker located 5 mm proximal to the sheath tip. Only the 28-mm SCB (Arctic Front Advance Pro, Medtronic, 10.5F shaft diameter, 8-mm tip length) was used in this study. The catheter handle has a deflection mechanism and a blue push button for balloon elongation for re-sheathing. The SCB is used in conjunction with a console (CryoConsole, Medtronic) providing the nitrous oxide (N2O) from a tank. The N2O is injected into the balloon via 8 injection jets.9
A 20-mm octapolar inner lumen spiral mapping catheter (Achieve, Medtronic, Minneapolis, MN, USA) was used in order to visualize PV signals. PVs were isolated in the following sequence: left superior, left inferior, right inferior, and right superior.
After obtaining PV occlusion by optimal alignment of the sheath, the catheter, and the PV, freezing cycles with a standard duration of 180–240 s were started. Target temperatures were − 40 °C and/or PV isolation (time to isolation) within 60 s. Freezing cycles were prematurely terminated when − 60 °C was reached or in case of phrenic nerve palsy. The endpoint of the ablation was the elimination of all PV potentials on the spiral mapping catheter. No “bonus” freezes were applied. During the thawing phase, the blue push button was advanced to elongate the balloon before + 20 °C was reached. At that temperature, the balloon deflates automatically.
Procedural differences with the novel cryoballoon
The NCB is used with the SMART FREEZE (Boston Scientific) console providing the N2O. The design of the NCB ablation system with a double-balloon layer, an internal balloon thermocouple at the shaft, and N2O delivery is very similar to that of the SCB. The pressure within the NCB remains stable from inflation to ablation, and the fluid flow during ablation is 7800 standard cubic centimeter per minute (sccm) compared to 7200 sccm for the SCB [10].
The sheath (POLARSHEATH, Boston Scientific) is a 12.7 French inner (15.9F outer) diameter deflectable sheath with a radiopaque marker 2.5 mm proximal to the sheath tip and a 155° angle of distal deflection. The distal end of the sheath appears softer to manual palpation compared to the NCB. The sheath is delivered without a stopcock.
The POLARx NCB catheter has a shaft diameter of 11.8 F and is currently available with a balloon diameter of 28 mm and with a long (12 mm) and a short (5 mm) catheter tip. For the purpose of this comparison, only the short-tip version of the NCB was used. The handle of the NCB has a steering lever with a tension nob and a slider switch (for manual deflation (only if > + 20 °C) and extension of the balloon for re-sheathing) which shows procedure status with an LED color code (green: ready; blue: inflation/thaw; flashing blue: ablation). No specific target temperatures were used because of limited available data, but reaching TTI < 60 s was attempted. Applications were prematurely terminated before freezing cycles are automatically terminated at a temperature of − 70 °C. Identical to the SCB, the balloon deflates automatically at a temperature of + 20 °C. Real-time signals were recorded with a 20-mm loop diameter octapolar spiral mapping catheter (POLARMAP, Boston Scientific).
Technical ex vivo characterization
In order to understand potential differences in cooling properties and temperature recording, the NCB and SCB were dissected (removal of the balloon) to describe and measure their technical specifications with focus on the position of the injection coil, the thermocouple, and the backflow of the N2O gas.
For semi-quantitative assessment of the ice cap formation as a surrogate of the heat transfer from the surrounding to the CB, three freezing cycles for three catheters in both groups were performed in a static water bath with 37 °C [7]. Pictures of the ice cap formation after 60, 120, 180, and 240 s in two perpendicular views were taken and the boundaries of the ice caps were delineated. The minimal and maximal ice coverage was used to characterize the homogeneity of their freezing capabilities over time.
Post-ablation management
Oral anticoagulation was continued for at least 2 months. All antiarrhythmic drugs were stopped after the procedure. This was an acute study and follow-up ended at hospital discharge.
Outcome measures
Technical differences, procedural parameters, failure rate (defined as catheter malfunction requiring a switch to a second CB catheter), acute efficacy, and safety are reported.
Acute efficacy was defined as PVI on a per patient and per PV basis using the CB. The number of freezing cycles per patient and per PV and the percentage of PVs which could be isolated with a single application (“single-shot isolation”) was determined. With regard to freezing properties, we report nadir temperatures, temperature at isolation of the PV and time to isolation (TTI), and the percentage of recorded real-time signals. In addition, procedure time, LA dwell time, net ablation time, and fluoroscopy time are reported.
Reported complications are limited to peri-procedural complications and post-procedural complications occurring before hospital discharge.
Statistical analysis
Continuous variables are presented as mean ± one standard deviation or as median and interquartile range (IQR) in case of skewed distribution. For continuous variables, comparisons were made using Student’s T-test, or Mann–Whitney U test, as appropriate. Discrete variables were compared using Fisher’s exact test. A p-value < 0.05 was considered to indicate statistical significance. Analysis was performed using SPSS (IBM SPSS Statistics, Version 23.0, Armonk, NY, USA).